ࡱ> gjf bjbj΀ 4Z+p__???SSS8dS40$lD$M4O4O4O4O4O4O4$58s4?@s4__4n!n!n!j_@?M4n!M4n!n!V(@@)!S>v%) 944041)xF9F9)F9?) n!s4s4^4F9 %: The University of Tennessee Office of Research Administration Medicare Coverage Analysis Determination of Qualifying Trial (Not applicable for device trials)  Medicare Coverage Analysis should be performed prior to the initiation of a clinical trial to assure the proper billing of services. The preliminary analysis may be performed by the PI/study coordinator. The Office of Research Administration (ORA) will assist in the process if requested. Please complete the checklist below, sign and forward to ORA. Please note that this is a tool only to assist you with your determination. SECTION I  _________________________________________ ____________________ Principal Investigator Signature Principal Investigator Printed Name Date SECTION II The Medicare National Coverage Determination (NCD) on Clinical Trials states that Medicare covers the routine costs of qualifying clinical trials, as well as reasonable and necessary items and services used to diagnose and treat complications arising from participation in all clinical trials. A qualifying trial is one that meets all 3 criteria in Parts I and II and at least one of the criteria outlined in Part III. If a study does not meet the criteria for a qualifying trial, then none of the routine costs (conventional care) can be billed to Medicare. If the trial is a qualifying trial, the Principal Investigator must be able to provide objective sources such as peer-reviewed literature or medical practice guidelines that support the designation of all conventional care performed in the study that is to be billed to Medicare. Please complete the questions below to assist you in determining if this study is a qualifying trial as defined by Medicare. PART I- REQUIREMENTS FOR MEDICARE COVERAGE OF ROUTINE COSTS OF DRUG TRIALS Question Yes No Notes1. Does the investigational item fall within a Medicare Benefit category (e.g., physicians' service, durable medical equipment, diagnostic test) and is not statutorily excluded from coverage (e.g., cosmetic surgery, hearing aids)?  FORMCHECKBOX   FORMCHECKBOX 2. The trial must not be designed exclusively to test toxicity or disease pathophysiology. Does the trial have therapeutic intent?  FORMCHECKBOX   FORMCHECKBOX 3. Does the trial enroll patients with a diagnosed disease (trials of diagnostic interventions may enroll healthy patients in order to have a proper control group)?  FORMCHECKBOX   FORMCHECKBOX  PART II DESIRABLE CHARACTERISTICS Desirable Characteristics Yes No If yes, specify/notes1. Is the principal purpose of the trial is to test whether the intervention potentially improves the participants' health outcomes?  FORMCHECKBOX   FORMCHECKBOX 2. Is the trial well-supported by available scientific and medical information or it is intended to clarify or establish the health outcomes of interventions already in common clinical use?  FORMCHECKBOX   FORMCHECKBOX 3. Does the trial meet the criteria of NOT unjustifiably duplicating existing studies?  FORMCHECKBOX   FORMCHECKBOX 4. Is the trial design is appropriate to answer the research question being asked in the trial?  FORMCHECKBOX   FORMCHECKBOX 5. Is the trial is sponsored by a credible organization or individual capable of executing the proposed trial successfully?  FORMCHECKBOX   FORMCHECKBOX  PART III DETERMINATION OF DEEMED TRIAL Question Yes No If yes, specify/notes1. Is the study funded by NIH, CDC, AHRQ, CMS, DOD or VA?  FORMCHECKBOX   FORMCHECKBOX  2. Is the study funded by a cooperative group that receives funding by NIH, CDC, AHRQ, CMS, DOD or VA?  FORMCHECKBOX   FORMCHECKBOX 3. Is the study conducted under an investigational new drug application (IND)? If yes, list IND#  FORMCHECKBOX   FORMCHECKBOX 4. Is the study exempt from an IND under 21CFR312.12(b)(1)?  FORMCHECKBOX   FORMCHECKBOX       PAGE \* MERGEFORMAT 2 Is the Sponsor reimbursing the institution for all study related procedures? YES  FORMCHECKBOX  NO  FORMCHECKBOX  If you answered YES, please sign and email the form to  HYPERLINK "mailto:mluchs@uthsc.edu" mluchs@uthsc.edu or it may be faxed to ORA at 901-448-3943. Make sure that this determination is consistent with the Informed Consent Form. If you answered NO, please complete Section II, sign and email the form to  HYPERLINK "mailto:mluchs@uthsc.edu" mluchs@uthsc.edu or fax to ORA at 901-448-3943. Principal Investigator Name: Department: Study Coordinator: Study Title: Study Sponsor: "=>X|}~ϿϯxcxXMA5AheNhV5OJQJheNhbe5OJQJheNh.OJQJheNhxqOJQJ(jheNhbeOJQJUmHnHuheNhbeOJQJheNh.5OJQJheNh]5CJOJQJaJheNh.5CJOJQJaJheNh{5CJOJQJaJheNhV5CJOJQJaJheNhxq5CJOJQJaJhhxq5CJOJQJaJhh5CJOJQJaJ>~Z [ \ f g h j k l V gd=%`gd{$a$gdVgdbe$a$gdu[v w x Y Z [ \ f g h i j k l V W 걥vhYG"heNh$5>*CJOJQJaJheNh$CJOJQJaJheNheN5>*OJQJh$5>*OJQJheNh$5>*OJQJ+jheNhbe5OJQJUmHnHuheNh$5OJQJheNhf5OJQJheNh{5OJQJheN5OJQJheNh.5OJQJheNhV5OJQJheNhbe5OJQJh5OJQJV W b c d ./0{|} $Ifgd]L- $Ifgd+,gd,LSgd$$a$gdVgd=%`W Y b c  ,-./056efkz{ٽ˽˽皌~rrfrheNhf5OJQJheNh=%`5OJQJheNh=%`5>*OJQJheNh,LS5>*OJQJheNheN5>*OJQJh5OJQJheNh.5OJQJheNh+-5>*OJQJheNh@5>*OJQJheNh$5>*OJQJheNh$5OJQJheNheN5OJQJ!{|} DrsKOQSUӿo]#jheNh,LSOJQJU#j heNh,LSOJQJU#jheNh,LSOJQJU#jheNh,LSOJQJUjheNh,LSOJQJUheNheNOJQJheNh,LSOJQJh]L-5OJQJheNh,LS5OJQJheNh,LS5CJOJQJaJheNheN5CJOJQJaJ$xkkkk $Ifgd+, $IfgdeN}kd$$Ifl0%| t0d&644 layt+,lmnviii $Ifgd+, $IfgdeNkd$$Ifl$0%| t0d&644 layt+,MPQxkkk $Ifgd+, $IfgdeN}kd $$Ifl0%| t0d&644 layt+,UVdefxy屦ypdyTDheNh+-5CJOJQJaJheNheN5CJOJQJaJheNh,LS5OJQJheN5OJQJheNh+-5OJQJheNh+-5>*OJQJheNheNOJQJheNOJQJheNhfOJQJheNh,LS5CJOJQJaJ#jheNh,LSOJQJU#jheNh,LSOJQJUheNh,LSOJQJjheNh,LSOJQJU|sssjjj]] $Ifgd+, gd+- gdfgd,LS}kd$$Ifl0%| t0d&644 layt+,  ǼǼǚLjǚvǼǚdǚ#jHheNh+-OJQJU#j6heNh+-OJQJU#jheNh+-OJQJUjheNh+-OJQJUh,LSh,LSOJQJh]L-OJQJheNh,LSOJQJheNh+-OJQJh 5OJQJheNh+-5OJQJheNh,LS5OJQJheNheN5OJQJ#xkk $Ifgd+, $Ifgd]L-}kd($$Ifl0%| t0d&644 layt+,viii $Ifgd+, $Ifgd]L-kd$$Ifl$0%| t0d&644 layt+, !"'(678JKYZ[`drsӣӑm#j heNh+-OJQJU#jP heNh+-OJQJU#jB heNh+-OJQJU#jheNh+-OJQJUh,LSh,LSOJQJh]L-OJQJheNh,LSOJQJheNh+-OJQJjheNh+-OJQJU#jheNh+-OJQJU*#\xk $Ifgd+, $Ifgd]L-}kd4$$Ifl0%| t0d&644 layt+,\]xkk $Ifgd+, $Ifgd]L-}kd $$Ifl0%| t0d&644 layt+,txxkk $Ifgd+, $Ifgd]L-}kd< $$Ifl0%| t0d&644 layt+,sw{|})/0Q|laULUah 5OJQJheNh]5OJQJheNh]OJQJheNh@5CJOJQJaJheNh@5OJQJheNh+-5>*OJQJheNh@5>*OJQJheNheNOJQJheNh+-OJQJ#jJ heNh,LSOJQJU#j heNh,LSOJQJUjheNh,LSOJQJUhOJQJheNh,LSOJQJ0xxxxxkk $Ifgd! gdf}kd $$Ifl0%| t0d&644 layt+,01lzmmm $Ifgd! $IfgdxkdX $$Ifl0%| t0d&644 laQT./34BCDVWefgiꯀq_qq#jheNhFOJQJUjheNhFOJQJUheNhFOJQJ#jheNhFOJQJU#jbheNhFOJQJUhOJQJ#j[heNhFOJQJU#j heNhFOJQJUjheNh]OJQJUheNh]OJQJheNhOJQJ%-.hxkk $Ifgd! $Ifgdzkd$$Ifl$0%| t0d&644 lahizzz $Ifgd!xkdN$$Ifl0%| t0d&644 laDFJKYZ[mn|}~ӶӤȕ}t}plah+,hbeOJQJhXChcohmHnHuhjhUh'jh'UheNh CJOJQJaJ#jheNhFOJQJU#jTheNhFOJQJUheNh]OJQJheNhFOJQJjheNhFOJQJU#jQheNhFOJQJU%EFzzz $Ifgd!xkd$$Ifl0%| t0d&644 la~||||||||wu|$a$ gd.xkd@$$Ifl0%| t0d&644 la *- gd.gdbegd{'()=AIRcdeꕊ~mamSm~Gh+,hf5OJQJh+,hV0J5OJQJh+,hV5OJQJ jh+,hV5OJQJUh+,h$5OJQJh+,h$OJQJh+,h< OJQJh+,hbe5OJQJ#jAh+,h;IOJQJU#jh+,h;IOJQJUjh+,hbeOJQJUh+,heNOJQJh+,hbeOJQJh+,h.OJQJ*-?Hdef޼Ӎӂӂ~zvgheNh CJOJQJaJhYh8hJ\fh+,hxqOJQJhbeh+,hV0J5OJQJ jh+,hV5OJQJUh+,hV5OJQJh+,hcoOJQJh+,hbe5OJQJh+,hbeOJQJh+,h$OJQJh+,h$5OJQJh+,hVOJQJ!21h:peN/ =!"#$% $$If!vh5|5#v|#v:V l t0d&65|5yt+,vDeCheck20vDeCheck21$$If!vh5|5#v|#v:V l$ t0d&65|5yt+,vDeCheck22vDeCheck23$$If!vh5|5#v|#v:V l t0d&65|5yt+,vDeCheck24vDeCheck25$$If!vh5|5#v|#v:V l t0d&65|5yt+,$$If!vh5|5#v|#v:V l t0d&65|5yt+,vDeCheck20vDeCheck21$$If!vh5|5#v|#v:V l$ t0d&65|5yt+,vDeCheck22vDeCheck23$$If!vh5|5#v|#v:V l t0d&65|5yt+,vDeCheck24vDeCheck25$$If!vh5|5#v|#v:V l t0d&65|5yt+,vDeCheck26vDeCheck27$$If!vh5|5#v|#v:V l t0d&65|5yt+,vDeCheck26vDeCheck27$$If!vh5|5#v|#v:V l t0d&65|5yt+,$$If!vh5|5#v|#v:V l t0d&65|5vDeCheck20vDeCheck21$$If!vh5|5#v|#v:V l$ t0d&65|5vDeCheck22vDeCheck23$$If!vh5|5#v|#v:V l t0d&65|5vDeCheck24vDeCheck25$$If!vh5|5#v|#v:V l t0d&65|5vDeCheck26vDeCheck27$$If!vh5|5#v|#v:V l t0d&65|5tDeCheck1tDeCheck2^ 02 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~_HmH nH sH tH @`@ NormalCJ_HaJmH sH tH DA`D Default Paragraph FontRi@R  Table Normal4 l4a (k (No List 6U@6 $ Hyperlink >*B*phjj ] Table Grid7:V044 coHeader  !4 @"4 co0Footer  !Vo2V ,LSDefault 7$8$H$!B*CJ_HaJmH phsH tH 6A6 0 Footer CharCJaJPK![Content_Types].xmlj0Eжr(΢Iw},-j4 wP-t#bΙ{UTU^hd}㨫)*1P' ^W0)T9<l#$yi};~@(Hu* Dנz/0ǰ $ X3aZ,D0j~3߶b~i>3\`?/[G\!-Rk.sԻ..a濭?PK!֧6 _rels/.relsj0 }Q%v/C/}(h"O = C?hv=Ʌ%[xp{۵_Pѣ<1H0ORBdJE4b$q_6LR7`0̞O,En7Lib/SeеPK!kytheme/theme/themeManager.xml M @}w7c(EbˮCAǠҟ7՛K Y, e.|,H,lxɴIsQ}#Ր ֵ+!,^$j=GW)E+& 8PK!Ptheme/theme/theme1.xmlYOo6w toc'vuر-MniP@I}úama[إ4:lЯGRX^6؊>$ !)O^rC$y@/yH*񄴽)޵߻UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSebORD۫qu gZo~ٺlAplxpT0+[}`jzAV2Fi@qv֬5\|ʜ̭NleXdsjcs7f W+Ն7`g ȘJj|h(KD- dXiJ؇(x$( :;˹! I_TS 1?E??ZBΪmU/?~xY'y5g&΋/ɋ>GMGeD3Vq%'#q$8K)fw9:ĵ x}rxwr:\TZaG*y8IjbRc|XŻǿI u3KGnD1NIBs RuK>V.EL+M2#'fi ~V vl{u8zH *:(W☕ ~JTe\O*tHGHY}KNP*ݾ˦TѼ9/#A7qZ$*c?qUnwN%Oi4 =3ڗP 1Pm \\9Mؓ2aD];Yt\[x]}Wr|]g- eW )6-rCSj id DЇAΜIqbJ#x꺃 6k#ASh&ʌt(Q%p%m&]caSl=X\P1Mh9MVdDAaVB[݈fJíP|8 քAV^f Hn- "d>znNJ ة>b&2vKyϼD:,AGm\nziÙ.uχYC6OMf3or$5NHT[XF64T,ќM0E)`#5XY`פ;%1U٥m;R>QD DcpU'&LE/pm%]8firS4d 7y\`JnίI R3U~7+׸#m qBiDi*L69mY&iHE=(K&N!V.KeLDĕ{D vEꦚdeNƟe(MN9ߜR6&3(a/DUz<{ˊYȳV)9Z[4^n5!J?Q3eBoCM m<.vpIYfZY_p[=al-Y}Nc͙ŋ4vfavl'SA8|*u{-ߟ0%M07%<ҍPK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 +_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!Ptheme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK] lmnolmnor Z ***-W {UsQ!$'+,V \0h "#%&()*r U e x ' 7 J Z |3CVfJZm}G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$ $&-!Vfl|rG$G$XX8@`(  b  C "? \  3 "? B S  ?h !XT$6 TCheck20Check21Check22Check23Check24Check25Check26Check274WKnDg[~3 B 2>3   Y[\jkWYab,.z{SSU U     ! " ` d rsw{)/./   Y[\jkWYab,.z{SSU U     ! " ` d rsw{)/./aadH7lț\-zfev"<**^*`o(. ^`hH. L^`LhH.   ^ `hH. jj^j`hH. :L:^:`LhH.   ^ `hH. ^`hH. L^`LhH.88^8`o(. ^`hH.  L ^ `LhH.   ^ `hH. xx^x`hH. HLH^H`LhH. ^`hH. ^`hH. L^`LhH.h ^`o(hH. ^`hH. pLp^p`LhH. @ @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PLP^P`LhH.ev7l\-@        |q                 QCCtl !?hV.W[ AUC+_!z[L ljx  .F~YJky @/V9<% n 8* C h 8GPNDLbmTxq^1ijp, >..Onn'N)Z)>Ov:;WK zflC+x! HQqw xEegz1 3 e; 6c s F$!t[!""H"vt#{ $$M$}%>%)&;&fU&F'J'HP'/(s3(|( )FM*j*(+T+}+ ,+,H,l,+-]L-.f/\090[C0Y2g]2b2y 3Ky3A4dY4j]4+h4l5'5f86W?6WA6_6 727h797s8+9X9@p:;1;N;|;<(<:<'@<mC<Z]<E`<e<s=Si=? ?|v?Y?@;@y@/AJAgAB6C}LCzCD\D&DRDgDyDE]EMEpUESYEbEFCFFFPFZF^G3hG;ICIDIRI|'J9JAJWK&KcKvK{K L{ILMYMeNPO!O_R_cu_=%`c b ]ba-c4d}d8,e`ve!fHfkVfJ\fg%}l1menooSGouoepqxqmr ssTsH4t,Htu(_uO%v3vRvnvL&wlPxSxl zz[z{_||}m}$.1{P9RV05Oa} #9<\Y? )eZe n< 1bae5q'ybPueN-B4.1VYU,-n@tr f(5}#7qYiI{uL{G co)5?dKKzv0[e;+#.KPqay |Z;BS`0 knZ)rI"#6u b27=TQ}t 2 /1X3\w"Mab<Eqz3XCyl!P1miH1LLT{Y( w@E[0^c6Y[B($&z+,Q.vWVl3 xugK9Tbep "~?Qf)8i `(-GNXkiiF.sP87i~[=e+EK]vwQfB*A}!yb]DmS/2j/Ng2#~9VXV!#>/iKLu CS.U=ltG$$:uh5Ap7G$HX$y/25-6AB{+} Go6?$5ED@,nc*}&4.LWr" B=QLVAc"[tlWn|*'=&byv v*Xh2CHZjBqC{ ' *p]|02Q@X@UnknownG*Ax Times New Roman5Symbol3. *Cx Arial7.{ @CalibriA BCambria Math"1hfc&8!x4dyy2QHX ?u[2!xx&Preliminary Medicare Coverage AnalysiskpkellerLuchs, Melanie S   Oh+'0 $ D P \hpx(Preliminary Medicare Coverage Analysis kpkellerNormalLuchs, Melanie S8Microsoft Office Word@P@x@R!՜.+,D՜.+,d  hp  Indiana Universityy 'Preliminary Medicare Coverage Analysis Title 8@ _PID_HLINKSA -mailto:mluchs@uthsc.eduC-mailto:mluchs@uthsc.eduC  !"#$%&'()*+,-/012345678:;<=>?@ABCDEFGHIJKLMNOPQRSTUWXYZ[\]_`abcdehilRoot Entry F<Ÿ!kData .1Table9^9WordDocument 4ZSummaryInformation(VDocumentSummaryInformation8^MsoDataStore@߯!!WDCDS1SMVLF==2@߯!!Item  PropertiesUCompObj y   F'Microsoft Office Word 97-2003 Document MSWordDocWord.Document.89q